Ipamorelin: What It Is, Where to Get It Prescribed, and What It Costs

Ipamorelin is a pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, two of them unnatural, which helps it survive long enough in the body to act. It is entirely synthetic. What it imitates is ghrelin, the stomach hormone that signals hunger and tells the pituitary to release growth hormone.

It is not growth hormone and contains none. It is a signal to the pituitary, and the pituitary decides how much to release: a secretagogue can only ask for what the gland is still able to give.

Ipamorelin was developed at Novo Nordisk in the 1990s from a chemistry programme built on an earlier compound, GHRP-1. The founding paper, in the European Journal of Endocrinology in 1998, called it "the first selective growth hormone secretagogue." The claim was specific: in pigs, the older peptides GHRP-6 and GHRP-2 released growth hormone but also raised ACTH and cortisol, whereas ipamorelin released growth hormone at comparable potency without raising either above what GHRH itself produced, even at more than 200 times the dose needed for half-maximal release. None of the compounds affected prolactin, FSH, LH or TSH.

It was later taken into human trials by Helsinn for postoperative ileus, covered below; that programme was discontinued. The compounded use — evening injections for sleep, recovery and body composition — grew up separately, through prescribers.

It is not an anabolic steroid; it does not bind the androgen receptor or suppress testosterone. It depends on a pituitary that can still respond — in complete growth hormone deficiency there is nothing for it to stimulate. And no regulator has approved it as a treatment for anything.

Ipamorelin binds the growth hormone secretagogue receptor, GHS-R1a, the receptor ghrelin uses; the 1998 work used receptor antagonists to show it acts there and not at the GHRH receptor. Activation produces a pulse of growth hormone rather than a sustained rise — in the human volunteer study below, a single episode of release peaked at about 40 minutes and fell to negligible levels at every dose.

Earlier GHRPs release growth hormone and cortisol together, which is undesirable for anything taken nightly for weeks; in pigs, ipamorelin did not. The FDA's 2024 review summarised the animal literature the same way — growth hormone release "without major effects on adrenocorticotropic hormone or cortisol levels" — but the human volunteer study measured growth hormone only, so in people the selectivity is inferred, not measured.

The pituitary listens to two inputs: GHRH from the hypothalamus and ghrelin-type signals from the gut. They act on different receptors and their effects are described as additive. That is the logic of CJC-1295 / Ipamorelin and Ipamorelin + Sermorelin: one compound supplies the GHRH signal, ipamorelin the ghrelin signal, and both converge on the same pulse.

Ghrelin receptors also sit on the nerves that drive stomach and intestinal movement. In rats subjected to abdominal surgery, intravenous ipamorelin shortened the time to first bowel movement (Journal of Pharmacology and Experimental Therapeutics, 2009), and later rat work in the Journal of Experimental Pharmacology in 2012 described faster gastric emptying. This is the mechanism that took ipamorelin into human trials; it is unrelated to the growth hormone axis.

A 2004 paper in Neuro Endocrinology Letters reported that ipamorelin evoked insulin release from pancreatic tissue of normal and diabetic rats. It is an in-vitro finding, and it cuts both ways: growth hormone itself raises blood glucose, which is why diabetes and impaired glucose tolerance are raised at intake.

Established in every species tested. In humans, a dose-escalation study in Pharmaceutical Research in 1999 gave healthy male volunteers intravenous ipamorelin at five dose levels and reported dose-proportional pharmacokinetics, a two-hour half-life and a single, sharp episode of growth hormone release at every dose. That study is the human pharmacology anchor. It measured growth hormone only — not sleep, body composition, strength or recovery — and it did not use the subcutaneous route.

Three rat papers describe skeletal effects. In Growth Hormone & IGF Research in 1999, adult female rats given ipamorelin for 15 days showed dose-dependent increases in longitudinal bone growth rate. In the Journal of Endocrinology in 2000, 12 weeks of continuous ipamorelin produced higher bone mineral content on DXA, attributed to larger bones rather than denser bone. In Growth Hormone & IGF Research in 2001, it counteracted the loss of muscle tension and bone formation caused by three months of high-dose methylprednisolone. None has a human counterpart.

A 2001 paper in Biochemical and Biophysical Research Communications runs against the marketing. In mice, twice-daily ipamorelin increased body weight, fat-pad weight, leptin and food intake; the authors concluded that secretagogues increase body fat by growth-hormone-independent mechanisms that likely include feeding. This does not mean ipamorelin makes people fatter; it means the animal evidence does not support "fat loss" as an effect, and nobody should tell you it does.

The rat work is positive. The human trial was not. A phase 2, multicentre, double-blind, placebo-controlled study in the International Journal of Colorectal Disease in 2014 randomised 114 adults undergoing bowel resection to intravenous ipamorelin or placebo twice daily for up to seven days. Median time to tolerating a solid meal was 25.3 hours with ipamorelin against 32.6 with placebo, not statistically significant, and no secondary endpoint separated from placebo. On those results the sponsor discontinued development. That is the only randomised trial of ipamorelin in patients ever published, and it was for a surgical indication by intravenous infusion.

Stated precisely: one pharmacokinetic and pharmacodynamic study in healthy male volunteers, which confirmed that intravenous ipamorelin releases growth hormone in people, and one randomised, placebo-controlled phase 2 trial in bowel-resection patients, which did not meet its endpoints. There are no randomised human trials of ipamorelin for sleep, recovery, body composition, ageing or any wellness use, and there are no human data for the subcutaneous route at all. The FDA's 2024 review looked and found none.

What exists instead is prescribing experience and a coherent mechanistic case — a legitimate basis for a physician to prescribe, and the honest description of where the compound stands.

• It does not establish that nightly subcutaneous ipamorelin changes body composition in adults. No trial has measured it.
• It does not establish any effect on sleep. The bedtime timing follows the physiology of the nocturnal pulse, not a sleep study.
• It does not establish long-term safety. The longest human exposure on record is seven days.
• It does not establish efficacy for any condition as an approved treatment. It is not approved for anything.

The pharmacology says what happens on night one: a pulse of growth hormone within the hour, gone by morning. What people report early is mostly about sleep — falling asleep more easily, or waking more rested. Some report nothing; some report a brief headache, flushing or hunger after the injection. None of this signals whether the course is working.

If a secretagogue is going to change anything measurable, this is the window prescribers describe, which is why baseline bloodwork is commonly required: IGF-1 at the start gives your physician something to compare against. Reports in this period concern recovery and body composition, and they are reports, not trial results. Treat the sleep reports as the most consistent thing prescribers describe, and the least measured.

There is no withdrawal and no rebound described in the literature; because ipamorelin asks the pituitary for a pulse rather than replacing growth hormone, the gland's own output is not suppressed. Rat work reported only a marginally reduced pituitary response after 15 days of dosing.

The directions are written in millilitres and insulin-syringe units because that is what you can read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated. Bedtime lands the pulse on top of the natural nocturnal release rather than after a meal, which is described as blunting the response. Monday through Friday with weekends off is the reviewed schedule; two nights off is how prescribers describe keeping the pituitary responsive. Your directions will say.

20 doses at five nights a week is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label.

Different receptors, same gland. Sermorelin is a GHRH analogue with a regulatory history and human trial data ipamorelin lacks; ipamorelin has the cleaner hormonal profile in animal work. Because the two signals are additive they are more often combined than chosen between, which is why Ipamorelin + Sermorelin exists.

Both act at the same receptor. Hexarelin belongs to the older, less selective generation of GHRPs that ipamorelin was designed to improve on for cortisol and prolactin. Ipamorelin is the one chosen when a course will run for weeks; hexarelin is a physician's choice when a stronger pulse is the priority.

The combination adds a GHRH analogue in the same vial. Prescribers who want the additive effect start with CJC-1295 / Ipamorelin; those who want to see how a patient responds to the ghrelin signal alone start here.